Author

G. Bervoets

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:scRNA-seq· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Approach:experimental assay· 1

Frequent Co-Authors

D. Lambrechts· 3 shared J. Pozniak· 3 shared J.-C. Marine· 3 shared O. Bechter· 3 shared A. Antoranz· 2 shared D. Pedri· 2 shared E. Landeloos· 2 shared E. Leucci· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. Lambrechts

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

NK cells contribute to resistance to anti-PD1 therapy in immune-excluded melanomas

E. Landeloos, J. Pozniak, N. Roda, A. de Visscher, A. Antoranz, Y. van Herck, G. Bervoets, F. M. Bosisio, V. Boecxstaens, A. Bassez, D. Lambrechts, P. Matthys, O. Bechter, J.-C. Marine

The paper identifies NK cells as contributors to resistance to anti-PD1 therapy in immune-excluded melanomas using single-cell RNA sequencing and spatial proteomics.

bioRxiv · Dec 14, 2023 · PreprintCancer Biology

A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanoma

J. Pozniak, D. Pedri, E. Landeloos, Y. Van Herck, A. Antoranz, P. Karras, A. Nowosad, S. Makhzami, G. Bervoets, M. Dewaele, L. Vanwynsberghe, S. Cinque, S. Kint, K. Vandereyken, T. Voet, , J.-C. Marine

This study identifies a TCF4/BRD4-dependent regulatory network that drives cross-resistance to ICB and targeted therapy in melanoma by analyzing scRNA-seq data from a longitudinal cohort.

bioRxiv · Aug 11, 2022 · PreprintCancer Biology

A neural crest stem cell-like state drives nongenetic resistance to targeted therapy in melanoma

O. Marin-Bejar, A. Rogiers, M. Dewaele, J. Femel, P. Karras, J. Pozniak, G. Bervoets, N. Van Raemdonck, D. Pedri, T. Swings, J. Demeulemeester, S. Vander Borght, F. Bosisio, J. J. van den Oord, I. Vanden Bempt, , J.-C. Marine

This study identifies a neural crest stem cell-like state in melanoma minimal residual disease that drives nongenetic resistance to MAPK-targeted therapy and shows that targeting FAK/SRC signaling can delay relapse.

bioRxiv · Dec 15, 2020 · PreprintCancer Biology